Background: Patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL) have
poor outcomes with currently available therapies, with a complete response (CR) rate of 8 …

Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the
multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28 …

Background: ZUMA-1 is a phase 1-2 multicenter, open-label study evaluating the safety and
efficacy of KTE-C19 in patients with refractory aggressive B-cell non-Hodgkin lymphoma. In …

The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and
survival among patients with refractory large B-cell lymphoma (LBCL) treated with …

Introduction: Chimeric antigen receptor modified T cells directed against CD19 (CART19)
achieve durable remissions in about 30-40% of relapsed or refractory (r/r) diffuse large B cell …

Background: Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell
therapy, has shown promising efficacy in refractory aggressive non-Hodgkin lymphoma in …

Abstract BACKGROUND: CTL019 (tisagenlecleucel) is an investigational chimeric antigen
receptor (CAR) T-cell therapy that identifies and eliminates CD19-expressing B cells …

Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …

Introduction Axi-cel is an autologous anti-CD19 CAR T-cell therapy approved by the US FDA
10/18/2017, for the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma …

CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …